Search

The article discusses the change in the definitions and treatment options for heart attack. Topics include the most common underlying cause of a heart attack, symptoms of a heart attack, and advice when having a suspicion that one may be having a heart attack. Also mentioned is initial treatment for a heart attack.

An 80-year-old man with a history of hypertension, diabetes, smoking, and lung cancer experienced a lack of efficacy during treatment with aspirin, clopidogrel, and atorvastatin for the prevention of thromboembolic events. Despite receiving this therapy, he continued to have recurrent episodes of right-sided weakness. The man underwent several procedures and was eventually stabilized with treatment and transferred to a nursing facility for further care. [Extracted from the article]

This article from Reactions Weekly describes two case reports of women aged 65-74 who developed anti-HMG-COA reductase antibody-associated immune-mediated necrotising myopathy while taking atorvastatin for hypercholesterolemia. Patient A experienced muscular symptoms and elevated creatine kinase levels after 5-6 years of atorvastatin use. Patient B also developed muscular symptoms after a similar duration of atorvastatin use. Both patients had strongly positive HMGCR antibodies. Atorvastatin was discontinued in both cases, and additional treatments such as glucocorticoids, immunoglobulins, and methotrexate were administered. The article suggests that the immune-mediated necrotising myopathy was a result of atorvastatin use. [Extracted from the article]

The article presents findings on the long-term effects of cholinesterase inhibitors (ChEIs) and memantine in patients with dementia with Lewy bodies (DLB). Key topics include the effectiveness of ChEIs in slowing cognitive decline compared to memantine and nonuse, the lack of difference in major adverse cardiovascular events between treatments, and the reduction in mortality risk within the first year of ChEI treatment.

Researchers from the University of Hassan 2 Casablanca in Morocco have conducted a study on the validation of a high-performance liquid chromatography (HPLC) method for quantifying atorvastatin and its impurities. The study aims to ensure the safety and effectiveness of medications by accurately determining active pharmaceutical ingredients and impurities. The results of the study confirm the precision, accuracy, and stability-indicating capabilities of the validated HPLC method, making it a robust and reliable tool for atorvastatin analysis in pharmaceutical quality control. The research contributes significantly to pharmaceutical research and quality control, reinforcing its role in ensuring medication safety and efficacy. [Extracted from the article]

Researchers at the University of California Davis conducted a study to evaluate the pharmacokinetics of atorvastatin, a medication used to treat lipid disorders, in cockatiels. The study found that a single oral dose of atorvastatin resulted in plasma concentrations that support its therapeutic use in cockatiels. The researchers recommended a starting dose of 20 mg/kg every 12 to 24 hours for the treatment of lipid disorders in cockatiels, pending further research on multidose use and efficacy. The study was supported by financial grants from UC Davis Academic Senate. [Extracted from the article]

A study conducted at Southwest Medical University in Sichuan, China, aimed to investigate the effectiveness of atorvastatin calcium tablets in relieving morphine tolerance in cancer pain patients. The study found that the combined treatment of atorvastatin calcium tablets and morphine effectively prolonged the time between morphine dose increments, alleviating morphine tolerance with high safety. The study also concluded that this treatment may provide insights into morphine tolerance treatment in cancer pain management. The research was peer-reviewed and published in the International Journal of Radiation Research. [Extracted from the article]

A study conducted at Guang'anmen Hospital in Beijing, China, investigated the effects of combining low-dose atorvastatin calcium with evolocumab on complement regulatory protein levels, lipid profiles, and cardiac function in patients with coronary heart disease (CHD). The study enrolled 180 CHD patients and randomly assigned them to either the control group (receiving low-dose atorvastatin calcium) or the research group (receiving a combination of low-dose atorvastatin calcium and evolocumab). Both groups showed reductions in blood lipid levels, but the research group had significantly lower levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol. The research group also exhibited greater enhancements in cardiac function indices and higher levels of complement regulatory proteins. The study concluded that the combined therapy shows promise for managing CHD. [Extracted from the article]

A recent study conducted at the Second Affiliated Hospital has found that triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer, is characterized by high cancer cell proliferation and poor patient prognosis. The study identified a protein kinase called PKMYT1 as a key driver of cholesterol synthesis in TNBC cells. The researchers discovered that downregulation of PKMYT1 inhibited the feedback upregulation of statin-mediated cholesterol biosynthesis and increased the drug sensitivity of atorvastatin in TNBC cells. This study provides new insights into the metabolic reprogramming of TNBC and suggests PKMYT1 as a potential target for therapeutic intervention. [Extracted from the article]

A 75-year-old man experienced secondary thrombotic microangiopathy (TMA) after taking clopidogrel and atorvastatin for dyslipidemia. The man had a history of chronic hypertension, dyslipidemia, type 2 diabetes, and ischaemic cardiopathy. He underwent a procedure and started dual antiplatelet therapy with clopidogrel and aspirin. Later, he was admitted to the emergency department with symptoms and was diagnosed with acute coronary syndrome. Further investigation revealed TMA, and it was determined that the interaction between clopidogrel and atorvastatin was the cause. The man's treatment with clopidogrel was discontinued, and he received methylprednisolone. He fully recovered his kidney function. [Extracted from the article]

A 35-year-old man developed necrotizing autoimmune myopathy while taking atorvastatin for hyperlipidemia. He had a medical history of autism, type 2 diabetes mellitus, hyperlipidemia, and hypertension. After experiencing leg pain and difficulty walking, he was admitted to the hospital. Lab results showed abnormal levels, and his medications, including atorvastatin, were stopped. A muscle biopsy confirmed the diagnosis of atorvastatin-induced necrotizing autoimmune myopathy, and he was treated with various medications, but his strength did not significantly improve. [Extracted from the article]

A study conducted at Purdue University in West Lafayette, Indiana, explores the potential benefits of continuous manufacturing over batch processing for antihyperlipidemic agents. Continuous manufacturing offers advantages such as shorter turnaround times, smaller footprint, higher productivity, adaptability, and consistent product quality. However, there are challenges in integrating the various technological steps into a coherent end-to-end continuous system. The study focuses on creating and implementing an end-to-end continuous manufacturing process for atorvastatin calcium, a commonly used statin for treating hypercholesterolemia. The research demonstrates significant improvements in cake yield, solvent retention, throughput, and productivity, highlighting the potential for the future of continuous pharmaceutical manufacturing. [Extracted from the article]

Researchers at PSG College of Pharmacy have conducted a study on the development and characterization of self nanoemulsifying solid (SNEDDS) of Atorvastatin calcium, an anti-hyperlipidemic agent. The aim of the study was to enhance the bioavailability of Atorvastatin calcium. The researchers used various solvents to determine the maximum solubility of the drug and constructed a pseudo-ternary phase diagram to identify the nanoemulsifying region. Different formulations were prepared with varying compositions of vegetable oil and non-ionic surfactant. The optimized system is expected to improve the dissolution of Atorvastatin calcium and enhance its bioavailability. [Extracted from the article]

A new study conducted by researchers at Emory University in Atlanta, Georgia, explores the potential of atorvastatin, a statin drug, in preventing hearing loss in patients with head and neck squamous cell carcinoma (HNSCC) who are receiving cisplatin-based chemoradiation. The study is a multi-center, randomized, placebo-controlled trial that aims to enroll up to 214 subjects at four U.S. sites. The primary endpoint of the study is the incidence of grade 2 hearing loss at 3 months after chemoradiation, with secondary endpoints including other treatment-related adverse events, overall survival, and disease-free survival. The research is funded by NIH/NIDCD and the clinical trial information can be found under NCT04915183. [Extracted from the article]

A study conducted at Harbin Medical University in Heilongjiang, China, examined the effectiveness and safety of combining atorvastatin calcium with ezetimibe in the treatment of coronary heart disease. The study included 95 individuals with coronary heart disease, with 45 in the control group receiving atorvastatin calcium monotherapy and 50 in the research group receiving a combination of atorvastatin calcium and ezetimibe. The research group showed a higher total effective rate and similar incidence of adverse reactions compared to the control group. Additionally, the research group experienced improvements in blood lipid levels, serum inflammatory indices, and oxidative stress indices. The study concluded that the combination therapy is effective and safe in treating coronary heart disease. [Extracted from the article]

A recent study conducted at Philadelphia University explored the effects of a combination treatment of biochanin A and atorvastatin on pancreatic cancer cells. The researchers found that this combination treatment resulted in enhanced anti-cancer effects, including inducing apoptosis, down-regulating cell cycle associated proteins, and reducing invasiveness in pancreatic cancer cells. These findings suggest that further investigation into this combination treatment could lead to new and improved treatments for pancreatic cancer. The study was funded by the Idaho INBRE Program, Mountain States Tumor and Medical Research Institute, and University Research Committee grants from Idaho State University. [Extracted from the article]

A recent study conducted in Chongqing, People's Republic of China, explored the role of atorvastatin in treating pulmonary artery hypertension (PAH). The study found that atorvastatin protected against PAH-induced increases in RVSP and Fulton's index in rats, and inhibited vascular remodeling by downregulating HIF-1 alpha and PDGF-BB. Atorvastatin also inhibited the activation of the AKT/ERK pathway and triggered apoptosis in human pulmonary artery smooth muscle cells exposed to hypoxia or PDGF-BB treatment. This research provides insights into the potential therapeutic effects of atorvastatin for PAH. [Extracted from the article]

Researchers from the Department of Pharmaceutics have developed and evaluated a gel-based formulation containing atorvastatin calcium (ATV) nanovesicles for the treatment of periodontitis. ATV is a lipid-lowering drug that has shown anti-inflammatory and anti-bacterial properties. The study found that the ATV-niosomal gel, when combined with scaling and root planing, demonstrated a prolonged effect and improved periodontal condition. The gel also exhibited antimicrobial activity against certain bacteria. This research provides potential advancements in the treatment of periodontitis using nanotechnology. [Extracted from the article]

A new report from New York City discusses the rare occurrence of drug-induced liver injury (DILI) caused by low-dose atorvastatin, a cholesterol-lowering drug. Atorvastatin is generally well-tolerated, but it can have adverse effects, including DILI. The report presents a case study of a 69-year-old woman who developed symptoms of fatigue, nausea, and abdominal pain after starting atorvastatin. Her liver function tests showed significant abnormalities, but her symptoms and liver function eventually improved after discontinuing the medication. The report emphasizes the importance of monitoring liver function in patients on low-dose statins, even if their baseline liver function is normal. Personalized approaches to statin therapy may be necessary to minimize the risk of adverse effects. [Extracted from the article]

A new report from St. John's Medical College in Karnataka, India discusses the impact of atorvastatin therapy on vascular endothelial function in early systemic sclerosis (SSc). The study aimed to determine if statins could improve endothelium-dependent vasodilation in patients with early SSc. The trial involved 71 eligible patients who were randomized into a statin group and a no-statin group. The results showed that atorvastatin did not improve endothelial function in early SSc, but it did stabilize skin tightening. No adverse events were reported. [Extracted from the article]

A recent study conducted by researchers at Army Medical University in Chongqing, China, explored the efficacy and toxicity of combining imatinib mesylate and atorvastatin calcium in the treatment of steroid-refractory chronic graft-versus-host disease (SR-cGVHD). The study involved 60 patients with SR-cGVHD and found that the combination therapy was effective in treating the disease and reducing target organ injury, particularly liver damage. The study also observed changes in T-cell subsets and adverse events associated with the treatment. The findings suggest that T-cell regulatory function may play a crucial role in the treatment process. [Extracted from the article]

A 46-year-old man experienced acute pancreatitis while being treated with dulaglutide for type 2 diabetes mellitus. He also showed a lack of effectiveness while taking atorvastatin and fenofibrate for hyperlipidemia. The man had a medical history of coronary artery disease, hyperlipidemia, type 2 diabetes mellitus, hypertension, and morbid obesity. Despite receiving treatment, his triglyceride levels remained high, indicating a lack of efficacy. [Extracted from the article]

A recent study conducted by researchers at King Saud University in Saudi Arabia has explored the use of innovative carbonated self-nanoemulsifying drug delivery systems (SNEDDS) to improve the stability of acid-labile drugs, using atorvastatin as a model drug. Atorvastatin is commonly prescribed for the treatment of hyperlipidemia. The study found that the SNEDDS formulation was able to enhance the dissolution of atorvastatin by about 1.5-fold compared to the pure drug formulation. Additionally, the incorporation of sodium bicarbonate in the carbonated SNEDDS significantly reduced the degradation rate of atorvastatin. These findings suggest that carbonated SNEDDS could be a promising approach to enhance the stability of acid-labile drugs. [Extracted from the article]

A 57-year-old woman experienced a lack of efficacy while being treated with atorvastatin and ezetimibe for hyperlipidemia. She presented with left arm pain and cramping, and further investigations revealed stenosis in her subclavian artery. Despite an increase in the dosage of atorvastatin, her condition did not improve. Lipoprotein (a) levels were found to be elevated, and ezetimibe was discontinued while evolocumab was initiated. After six months, her condition showed improvement under evolocumab. [Extracted from the article]

A recent study conducted in Tamil Nadu, India compared the side effects, patient outcomes, and healthcare costs of atorvastatin and rosuvastatin therapies for managing hyperlipidemia and preventing cardiovascular diseases. The study found that while both statins effectively reduced LDL cholesterol, rosuvastatin had higher patient adherence but incurred higher healthcare costs. The research highlights the importance of individualized statin therapy that considers both clinical outcomes and economic constraints, particularly in settings with limited healthcare resources. This information can inform more tailored and cost-effective treatment strategies for patients. [Extracted from the article]

A recent study published in Drug Week discusses the development of a new chromatographic protocol for determining the enantiomeric purity of atorvastatin (ATV) calcium salt, a commonly used antihyperlipidemic agent. The current method described in the European Pharmacopoeia (EP) is time-consuming and requires a large volume of solvent. The researchers developed an alternative method using a different column and mobile phase, which resulted in a faster analysis time and reduced solvent consumption. The method was found to be linear and effective in separating the enantiomeric impurity peak from other ATV impurities. This research provides valuable insights for improving the analysis of ATV calcium salt. [Extracted from the article]

A recent study conducted by researchers at Pharos University in Egypt explored the potential of repurposing the drug Atorvastatin calcium for the treatment of breast cancer. The researchers developed gelucire-based solid lipid nanoparticles (SLNs) decorated with lactoferrin (Lf) as a targeting ligand to enhance the drug's tumor-targeting capabilities. In vitro and in vivo assessments showed that the Lf-decorated-ATR Ca-SLNs demonstrated improved anti-tumor activity compared to undecorated ATR Ca-SLNs and the free drug. The study suggests that this drug repurposing approach could be a promising strategy for the effective management of breast cancer. [Extracted from the article]

A 50-year-old woman developed necrotizing myopathy while being treated with atorvastatin and rosuvastatin for unstable angina. She experienced weakness and pain in her lower limbs, followed by a sudden decrease in upper limb strength. Examination revealed severely diminished muscle power and absent deep tendon reflexes. The woman's muscle biopsy confirmed necrosis and inflammation, indicating necrotizing myopathy caused by the medications. Treatment involved discontinuing atorvastatin and rosuvastatin, starting prednisolone, and undergoing haemodialysis and plasmapheresis. After several weeks, the woman experienced significant improvement and regained her ability to walk unassisted. [Extracted from the article]

A recent study conducted by the Lithuanian University of Health Sciences examined the impact of gene variants on the long-term treatment of acute coronary syndromes with atorvastatin. The study found that patients with certain gene variants had lower responses to atorvastatin treatment compared to patients without these variants. The researchers concluded that the CYP2C19 gene variant may significantly affect the personalization of atorvastatin therapy in patients requiring LDL lipid-lowering treatment. This research provides valuable insights into the effectiveness of lipid-lowering therapies and the role of genetic variability in drug metabolism. [Extracted from the article]

2A Angina >CADUET Pfizer Rx Calcium channel blocker (CCB) + HMG-CoA reductase inhibitor. Amlodipine (as besylate), atorvastatin (as calcium); 2.5mg/10mg, 2.5mg/20mg, 2.5mg/40mg, 5mg/10mg, 5mg/20mg, 5mg/40mg, 5mg/80mg, 10mg/10mg, 10mg/20mg, 10mg/40mg, 10mg/80mg; [...]

>CADUET Pfizer Rx Calcium channel blocker (CCB) + HMG-CoA reductase inhibitor. Amiodipine (as besylate), atorvastatin (as calcium); 2.5mg/10mg, 2.5mg/20mg, 2.5mg/40mg, 5mg/10mg, 5mg/20mg, 5mg/40mg, 5mg/80mg, 10mg/10mg, 10mg/20mg, 10mg/40mg, 10mg/80mg; tabs. Indications: [...]

2A Angina >CADUET Pfizer Rx Calcium channel blocker (CCB) + HMG-CoA reductase inhibitor. Amlodipine (as besylate), atorvastatin (as calcium); 2.5mg/10mg, 2.5mg/20mg, 2.5mg/40mg, 5mg/10mg, 5mg/20mg, 5mg/40mg, 5mg/80mg, 10mg/10mg, 10mg/20mg, 10mg/40mg, 10mg/80mg; [...]

A recent study conducted by the College of Medicine Chang Gung University examined the clinical outcomes of different fixed-dose combination (FDC) regimens for patients with hypertension and hypercholesterolemia. The study found that treatment with an FDC of amlodipine and high-dose atorvastatin resulted in a lower risk of cardiovascular outcomes compared to treatment with a free combination or a similar FDC with a lower dose of atorvastatin. The research suggests that FDC regimens may be beneficial for patients with concurrent hypertension and hypercholesterolemia. [Extracted from the article]

A retrospective cohort study conducted at Hebei North University in China examined the effects of different doses of atorvastatin on patients with cardiorenal syndrome type-2. The study analyzed medical records of 113 patients and grouped them based on the dosage of atorvastatin they received. The results showed that medium-dose (20mg/day) atorvastatin had the same therapeutic effect as high-dose (40mg/day) treatment, improving cardiac and renal function and reducing inflammatory reactions. No adverse events were reported during the treatment process. This study suggests that medium-dose atorvastatin can effectively protect the heart and kidneys of patients with cardiorenal syndrome type-2. [Extracted from the article]

A 66-year-old woman experienced cutaneous vasculopathy of the breast while undergoing hormonal treatment with tamoxifen and lack of efficacy during treatment with atorvastatin for hypertriglyceridemia. She had previously undergone breast conserving surgery and radiation therapy for invasive ductal cancer. The woman also had a history of sarcoidosis and had undergone breast reduction surgery. The surgeon suspected a possible relationship with radiation therapy and prescribed ibuprofen and other medications. The woman's condition eventually resolved with treatment. It was concluded that she developed radiation-induced cutaneous vasculopathy of the breast, with tamoxifen playing a role in its occurrence. [Extracted from the article]

This article discusses a clinical trial, NCT06382974, that is investigating the effects of combining Atorvastatin and b-TCP on bone defects after jaw cyst removal. The trial will use CBCT-based volumetric analysis to measure the volume of the bone defects and assess bone regeneration. The study aims to find alternative bone grafting materials and explore the potential of statins to stimulate bone growth. The trial is interventional and primarily focused on treatment. The study is not yet recruiting participants and will involve 10 volunteers who meet specific inclusion criteria. It will take place in Egypt and is expected to be completed by March 2026, with Yara Gamal Mohamed Mahmoud from Cairo University as the responsible party. [Extracted from the article]

A recent study conducted by researchers at Xiang'an Hospital of Xiamen University explores the potential association between atorvastatin, a medication commonly prescribed for cardiovascular disease prevention, and erectile dysfunction (ED). The study utilized real-world data from the FAERS database and employed Mendelian randomization to assess causality. The findings suggest that atorvastatin use is associated with an increased risk of ED and indicate a causal relationship. The researchers emphasize the importance of considering potential adverse effects, such as ED, when prescribing atorvastatin for cardiovascular disease prevention. Further research and clinical monitoring are needed to better understand the underlying mechanisms and develop appropriate strategies to mitigate this side effect. [Extracted from the article]

A recent study conducted by researchers at Comenius University in Bratislava, Slovakia explored the outcomes and predictive factors of autologous bone marrow cells (BMCs) therapy in patients with "no-option" critical limb ischemia (CLI). The study found that patients who received atorvastatin treatment before BMCs treatment had significantly increased concentrations of bone marrow-derived mononuclear cells (BM-MNCs) and improved transcutaneous oxygen pressure (TcPO2), as well as reduced pain scale. Additionally, patients treated with renin-angiotensin system (RAS)-acting agents also experienced reduced pain scale after BMCs treatment. The study identified C-reactive protein (CRP) and TcPO2 as prognostic factors for responders, while CRP, ankle-brachial index (ABI), and BM-MNCs concentration were identified as prognostic factors for super-responders. The findings suggest that atorvastatin and RAS-acting agents may have a positive impact on the efficacy of BMCs therapy in CLI patients. [Extracted from the article]

Researchers at Hawler Medical University have conducted a study on antihyperlipidemic agents, specifically focusing on atorvastatin calcium (ATV). The study aimed to improve the solubility properties of ATV by using various hydrotropic agents in the formation of solid dispersion-based hydrotropic blends. The researchers prepared different formulations of ATV using different hydrotropic agents and found that certain formulations significantly enhanced the solubility ratio of ATV. The study concluded that solid dispersion-based hydrotropic blends can be used to improve the solubility of practically insoluble drugs. [Extracted from the article]

A recent study conducted by researchers at Hebei Medical University explored the potential of atorvastatin, a statin commonly used to lower cholesterol levels, in inhibiting aortic valve calcification (AVC), a cardiovascular disease and risk factor for sudden death. The study found that atorvastatin significantly inhibited the calcification of valve interstitial cells and enhanced autophagy, a process that removes damaged cellular components, in these cells. This was achieved by inhibiting the NF-kB signaling pathway and reducing the expression of inflammatory factors. The findings suggest that atorvastatin may be effective in alleviating valve interstitial cell calcification and improving AVC. [Extracted from the article]

A recent study conducted at the First Hospital of Hebei Medical University in China explored the effects of genetic variations in the low-density lipoprotein receptor (LDLR) gene on dyslipidemia, a risk factor for atherosclerotic cardiovascular disease. The study focused on a Han Chinese population in northern China and examined the impact of LDLR polymorphisms on baseline serum lipid levels and the therapeutic efficacy of atorvastatin, an antihyperlipidemic agent. The researchers identified several polymorphisms that were associated with serum lipid levels and the response to atorvastatin treatment. The study highlights the importance of genetic profiling in tailoring therapeutic strategies for dyslipidemia and suggests the integration of genetic testing into patient management to improve care. [Extracted from the article]

This document provides information about a clinical trial that is currently recruiting participants. The trial aims to compare the effectiveness of two different medications, atorvastatin and rosuvastatin, in reducing the risk of stroke in patients with acute ischemic stroke. The trial will involve 600 participants and is expected to be completed by May 10, 2025. The eligibility criteria for participants are outlined, and contact information for the primary investigator is provided. The document also includes keywords related to the study, such as anticholesteremic agents, antiplatelet agents, and stroke. [Extracted from the article]

A recent report from the Faculty of Pharmacy in Semarang, Indonesia, discusses the in vitro equivalence of eight generic atorvastatin calcium products with the innovator brand, Lipitor. The study used comparative dissolution testing to evaluate the performance of these products. The results showed that four out of the eight generic products were bioequivalent to the innovator brand. This research provides valuable information for healthcare professionals and patients in Indonesia who use atorvastatin calcium for the treatment of hyperlipidemia. [Extracted from the article]

This article from Reactions Weekly describes four cases of angioedema, a condition characterized by swelling of the face, tongue, and lips, in patients who were being treated with atorvastatin or rosuvastatin. The patients ranged in age from 58 to 64 years and included both men and women. In each case, the angioedema was determined to be a side effect of the statin medication, and the symptoms resolved after discontinuation of the medication. These cases highlight the importance of monitoring patients for potential adverse reactions when prescribing statins. [Extracted from the article]

This document provides information about a clinical trial in Egypt for the treatment of ischemic stroke. The trial, NCT06358313, aims to enroll 600 participants who have experienced a minor acute ischemic stroke or a high-risk transient ischemic attack. The study will compare the effectiveness of two drugs, atorvastatin and rosuvastatin, in reducing the risk of stroke recurrence. The trial will also assess the safety and tolerability of these medications using measures such as the National Institute of Health Stroke Scale (NIHSS) and the Modified Rankin Scale (mRS). The trial is set to run from April 2024 to April 2025. [Extracted from the article]

A study conducted by researchers at Jagiellonian University College of Medicine in Krakow, Poland, has found that a three-day administration of atorvastatin, a type of statin medication, can reduce the activity of coagulation factors FVII and FXI in patients with prior venous thromboembolism (VTE) and healthy subjects. The study also observed favorable modifications in fibrin clot properties as a result of the statin administration. These findings suggest that statins may have antithrombotic effects and potentially reduce the risk of VTE. However, further research is needed to confirm these preliminary results. [Extracted from the article]

A 67-year-old man developed immune-mediated necrotizing myopathy while being treated with atorvastatin for hyperlipidemia. He experienced progressive muscle weakness and eventually became completely paralyzed, requiring intubation. Tests revealed elevated levels of certain antibodies, confirming a diagnosis of statin-induced immune-mediated necrotizing myopathy. The man was treated with methylprednisolone, immune-globulin, and rituximab, which led to a resolution of his symptoms. [Extracted from the article]

A new report from the CSIR - Central Drug Research Institute in Uttar Pradesh, India, explores the potential herb-drug interactions between herbal slimming products (HSPs) and the drug atorvastatin (ATS), which is used to treat hyperlipidemia. The study found that HSPs can enhance the permeability and inhibit the metabolism of ATS, leading to increased bioavailability of the drug. Additionally, co-administration of HSPs with ATS resulted in reduced fat content, inflammatory cytokines, and lipid levels, as well as increased serum HDL levels. The researchers recommend caution and dose adjustment when using HSPs and ATS together. [Extracted from the article]

This article from Reactions Weekly describes two case studies of men who experienced decreased pregnenolone secretion while taking atorvastatin, a medication commonly used to lower cholesterol. The first patient, a 58-year-old man with a history of acute cerebral circulation disorder, reported symptoms such as shortness of breath, increased blood pressure, daytime sleepiness, decreased libido, and weakened erections. The second patient, a 64-year-old man with a history of acute myocardial infarction, experienced similar symptoms. Both patients had significant decreases in pregnenolone levels, leading to a diagnosis of decreased pregnenolone secretion secondary to atorvastatin. [Extracted from the article]

A 59-year-old woman developed immune-mediated necrotising myopathy while taking atorvastatin for dyslipidaemia. She also experienced reactive leukocytosis and hyperglycaemia while being treated with methylprednisolone for the same condition. The woman had a history of anxiety disorder, hypertension, obesity, and dyslipidaemia. She presented with muscle weakness and myalgias that had progressively worsened over the past few months. After discontinuing atorvastatin and receiving treatment with methylprednisolone, her symptoms improved, but she experienced transient elevations in liver enzymes, blood glucose levels, and white blood cell count. She was discharged with prednisone, but due to pharmacy issues, she had to be readmitted and treated with IV methylprednisolone again before being discharged a second time. [Extracted from the article]